Skip to main content

Advertisement

SpringerLink
Log in

Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric Cancer at High Risk of Recurrence—The PIPAC-OPC4 Study

  • Peritoneal Surface Malignancy
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Patients with gastric adenocarcinoma (GAC) are at high risk of peritoneal recurrence despite perioperative chemotherapy and radical resection. This study evaluated feasibility and safety of laparoscopic D2 gastrectomy in combination with pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Methods

This was a prospective, controlled bi-institutional study in patients with GAC at high risk of recurrence treated with PIPAC with cisplatin and doxorubicin (PIPAC C/D) after laparoscopic D2 gastrectomy. High risk was defined as a poorly cohesive subtype with predominance of signet-ring cells, clinical stage ≥ T3 and/or ≥ N2, or positive peritoneal cytology. Peritoneal lavage fluid was collected before and after resection. Cisplatin (10.5 mg/m2) and doxorubicin (2.1 mg/m2) were aerosolized after anastomosis (flow 0.5–0.8 ml/s, maximum pressure 300 PSI). Treatment was feasible and safe if ≤ 20% had Dindo–Clavien ≥ 3b surgical complications or CTCAE ≥ 4 medical adverse events within 30 days. Secondary outcomes were length of stay (LOS), peritoneal lavage cytology, and completion of postoperative systemic chemotherapy.

Results

Twenty-one patients were treated with a D2 gastrectomy and PIPAC C/D. The median age was 61 years (range 24–76), there were eleven female patients, and 20 patients had preoperative chemotherapy. There was no mortality. Two patients had grade 3b complications that were potentially related to PIPAC C/D (one anastomotic leakage, and one late duodenal blow-out). One patient had severe neutropenia, and nine patients had moderate pain. The LOS was 6 days (4–26). One patient had positive peritoneal lavage cytology before resection, and none were positive after. Fifteen patients had postoperative chemotherapy.

Conclusions

Laparoscopic D2 gastrectomy in combination with PIPAC C/D is feasible and safe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005–20.

    CAS  PubMed  Google Scholar 

  2. Waddell T, Verheij M, Allum W, et al. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014;40:584–91.

    CAS  PubMed  Google Scholar 

  3. Hendriksen BS, Brooks AJ, Hollenbeak CS, et al. The impact of minimally invasive gastrectomy on survival in the USA. J Gastrointest Surg. 2020;24:1000–9.

    PubMed  Google Scholar 

  4. Straatman J, van der Wielen N, Cuesta MA, et al. Minimally invasive versus open total gastrectomy for gastric cancer: a systematic review and meta-analysis of short-term outcomes and completeness of resection: surgical techniques in gastric cancer. World J Surg. 2016;40:148–57.

    PubMed  Google Scholar 

  5. Bringeland EA, Wasmuth HH, Grønbech JE. Perioperative chemotherapy for resectable gastric cancer — what is the evidence? Scand J Gastroenterol. 2017;52:647–53.

    PubMed  Google Scholar 

  6. Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12:347–53.

    PubMed  Google Scholar 

  7. Spolverato G, Ejaz A, Kim Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg. 2014;219:664–75.

    PubMed  Google Scholar 

  8. Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622–8.

    CAS  PubMed  Google Scholar 

  9. Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236–42.

    CAS  PubMed  Google Scholar 

  10. Coccolini F, Catena F, Glehen O et al. Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis. Eur J Surg Oncol. 2016.

  11. Kim KW, Chow O, Parikh K, et al. Peritoneal carcinomatosis in patients with gastric cancer, and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. Am J Surg. 2014;207:78–83.

    PubMed  Google Scholar 

  12. Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer. Lancet. 2016;388:2654–64.

    PubMed  Google Scholar 

  13. Khan H, Johnston FM. Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease. J Surg Oncol. 2022;125:1176–82.

    PubMed  PubMed Central  Google Scholar 

  14. Takebayashi K, Sonoda H, Shimizu T, et al. Successful surgical approach for a patient with encapsulating peritoneal sclerosis after hyperthermic intraperitoneal chemotherapy: a case report and literature review. BMC Surg. 2014;14:57.

    PubMed  PubMed Central  Google Scholar 

  15. Ji ZH, Peng KW, Li Y. Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer. Transl Gastroenterol Hepatol. 2016;1:69.

    PubMed  PubMed Central  Google Scholar 

  16. De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol. 2014;110:291–7.

    PubMed  Google Scholar 

  17. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583–92.

    CAS  PubMed  Google Scholar 

  18. Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697–708.

    CAS  PubMed  Google Scholar 

  19. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53–63.

    CAS  PubMed  Google Scholar 

  20. Kobayashi D, Ishigami H, Kanda M, et al. Phase I study of intraperitoneal administration of paclitaxel combined with S-1 plus cisplatin for gastric cancer with peritoneal metastasis. Oncology. 2020;98:48–52.

    CAS  PubMed  Google Scholar 

  21. Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018;36:1922–9.

    CAS  PubMed  Google Scholar 

  22. Desiderio J, Chao J, Melstrom L, et al. The 30-year experience—A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer. 2017;79:1–14.

    PubMed  PubMed Central  Google Scholar 

  23. Reymond MA, Hu B, Garcia A, et al. Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg Endosc. 2000;14:51–5.

    CAS  PubMed  Google Scholar 

  24. Solass W, Hetzel A, Nadiradze G, et al. Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc. 2012;26:1849–55.

    PubMed  Google Scholar 

  25. Solass W, Kerb R, Murdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21:553–9.

    PubMed  Google Scholar 

  26. Khosrawipour V, Khosrawipour T, Kern AJ, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol. 2016;142:2275–80.

    CAS  PubMed  Google Scholar 

  27. Graversen M, Detlefsen S, Bjerregaard JK, et al. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol. 2018;10:1758835918777036.

    PubMed  PubMed Central  Google Scholar 

  28. Alyami M, Hubner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20:e368–77.

    PubMed  Google Scholar 

  29. Graversen M, Detlefsen S, Fristrup C, et al. Adjuvant pressurized IntraPeritoneal aerosol chemotherapy (PIPAC) in resected high-risk colon cancer patients—study protocol for the PIPAC-OPC3 Trial. A prospective, controlled phase 2 study. Pleura Peritoneum. 2018;3:20180107.

    PubMed  PubMed Central  Google Scholar 

  30. Alyami M, Bonnot PE, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2021;47:123–7.

    PubMed  Google Scholar 

  31. Di Giorgio A, Schena CA, El Halabieh MA, et al. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis. Surg Oncol. 2020;34:270–5.

    PubMed  Google Scholar 

  32. Nadiradze G, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20:367–73.

    PubMed  Google Scholar 

  33. Gockel I, Jansen-Winkeln B, Haase L, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric cancer patients with peritoneal metastasis (PM): results of a single-center experience and register study. J Gastric Cancer. 2018;18:379–91.

    PubMed  PubMed Central  Google Scholar 

  34. Ellebæk SB, Graversen M, Detlefsen S, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study. Clin Exp Metastasis. 2020;37:325–32.

    PubMed  Google Scholar 

  35. Struller F, Horvath P, Solass W, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019;11:1758835919846402.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Khomyakov V, Ryabov A, Ivanov A, et al. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2). Pleura Peritoneum. 2016;1:159–66.

    PubMed  PubMed Central  Google Scholar 

  37. Tempfer CB, Celik I, Solass W, et al. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. Gynecol Oncol. 2014;132:307–11.

    CAS  PubMed  Google Scholar 

  38. Robella M, Hubner M, Sgarbura O, et al. Feasibility and safety of PIPAC combined with additional surgical procedures: PLUS study. Eur J Surg Oncol. 2022;48:2212–7.

    PubMed  Google Scholar 

  39. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.

    PubMed  PubMed Central  Google Scholar 

  40. Common terminology criteria for adverse events (CTCAE), version 4.0. National Institutes of Health, National Cancer Institute, November 2016. In.

  41. Tempfer CB, Giger-Pabst U, Seebacher V, et al. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol. 2018;150:23–30.

    CAS  PubMed  Google Scholar 

  42. Graversen M, Fristrup C, Kristensen TK, et al. Detection of free intraperitoneal tumour cells in peritoneal lavage fluid from patients with peritoneal metastasis before and after treatment with pressurised intraperitoneal aerosol chemotherapy (PIPAC). J Clin Pathol. 2019;72:368–72.

    CAS  PubMed  Google Scholar 

  43. Kim HH, Hyung WJ, Cho GS, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report—a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg. 2010;251:417–20.

    PubMed  Google Scholar 

  44. Lee HJ, Hyung WJ, Yang HK, et al. Short-term outcomes of a multicenter randomized controlled trial comparing laparoscopic distal gastrectomy with D2 lymphadenectomy to open distal gastrectomy for locally advanced gastric cancer (KLASS-02-RCT). Ann Surg. 2019;270:983–91.

    PubMed  Google Scholar 

  45. Wang Z, Zhang X, Liang J, et al. Short-term outcomes for laparoscopy-assisted distal gastrectomy for body mass index ≥30 patients with gastric cancer. J Surg Res. 2015;195:83–8.

    PubMed  Google Scholar 

  46. Guerrini GP, Esposito G, Magistri P, et al. Robotic versus laparoscopic gastrectomy for gastric cancer: the largest meta-analysis. Int J Surg. 2020;82:210–28.

    PubMed  Google Scholar 

  47. Herrera-Almario G, Strong VE. Minimally invasive gastric surgery. Ann Surg Oncol. 2016;23:3792–7.

    PubMed  PubMed Central  Google Scholar 

  48. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    CAS  PubMed  Google Scholar 

  49. Graversen M, Detlefsen S, Pfeiffer P, et al. Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey. Clin Exp Metastasis. 2018;35:103–8.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The study group would like to acknowledge Michael Hareskov Larsen, MD, PhD and Nicolaj Markus Stilling, MD for their clinical work with the patients. Further, the study group would like to thank the two research nurses Ulla Krogstrup Tecedor at Odense University Hospital, Odense, Denmark, and Maria Lampi at Karolinska University Hospital, Stockholm, Sweden for their ongoing, valuable work with the patients and authorities as well as data gathering and coordination of the study.

Author information

Authors and Affiliations

  1. Odense PIPAC Center, Odense University Hospital, Odense, Denmark

    Martin Graversen MD, PhD, A. P. Ainsworth MD, PhD, A. P. Bjarnesen MD, S. Detlefsen MD, PhD, S. B. Ellebaek MD, PhD, C. W. Fristrup MD, PhD, P. Pfeiffer MD, PhD, L. S. Tarpgaard MD, PhD & M. B. Mortensen MD, PhD, DMSci

  2. Department of Surgery, Odense University Hospital, Odense, Denmark

    Martin Graversen MD, PhD, A. P. Ainsworth MD, PhD, A. P. Bjarnesen MD, S. B. Ellebaek MD, PhD, C. W. Fristrup MD, PhD & M. B. Mortensen MD, PhD, DMSci

  3. OPEN - Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark, Odense, Denmark

    Martin Graversen MD, PhD

  4. Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

    Martin Graversen MD, PhD, A. P. Ainsworth MD, PhD, S. Detlefsen MD, PhD, P. Pfeiffer MD, PhD, L. S. Tarpgaard MD, PhD & M. B. Mortensen MD, PhD, DMSci

  5. Department of Upper Abdominal Diseases, Karolinska University Hospital and Division of Surgery and Oncology, CLINTEC, Karolinska Institutet, Stockholm, Sweden

    I. Rouvelas MD, PhD, L. Lundell MD, PhD, M. Nilsson MD, PhD & A. Tsekrekos MD

  6. Department of Pathology, Odense University Hospital, Odense, Denmark

    S. Detlefsen MD, PhD

  7. Department of Oncology, Karolinska University Hospital and Division of Surgery and Oncology, CLINTEC, Karolinska Institutet, Stockholm, Sweden

    M. G. Liljefors MD, PhD

  8. Department of Oncology, Odense University Hospital, Odense, Denmark

    P. Pfeiffer MD, PhD & L. S. Tarpgaard MD, PhD

Authors
  1. Martin Graversen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Rouvelas MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. P. Ainsworth MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. P. Bjarnesen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Detlefsen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. B. Ellebaek MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. W. Fristrup MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. G. Liljefors MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. Lundell MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Nilsson MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P. Pfeiffer MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. L. S. Tarpgaard MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A. Tsekrekos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M. B. Mortensen MD, PhD, DMSci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Graversen MD, PhD.

Ethics declarations

The authors have no commercial interests. No financial support was received for this study. The Accutron® Thera injector/Medtron AG was provided for free through Gothia Medical AB to Karolinska University Hospital during the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Graversen, M., Rouvelas, I., Ainsworth, A.P. et al. Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric Cancer at High Risk of Recurrence—The PIPAC-OPC4 Study. Ann Surg Oncol 30, 4433–4441 (2023). https://doi.org/10.1245/s10434-023-13278-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-13278-w

Search

Navigation